• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Preclinical

Improving immune activity may decrease Alzheimer’s disease pathology [PreClinical]

byChristine YoonandJessica Lau
February 19, 2016
in Preclinical
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

 

1. In a mouse model of Alzheimer’s disease (AD), blocking the programmed death-1 (PD-1) pathway with anti-PD-1 antibody treatment increased the population of infiltrating myeloid cells in the brain.

2. Mice that received two rounds of anti-PD-1 antibody treatment showed improved memory and clearance of amyloid-β plaques in the hippocampus and cerebral cortex regions.

Evidence Rating Level: 2 (Good)

Study Rundown: Alzheimer’s disease is a condition that is marked by progressive memory loss and the formation of amyloid-β (Aβ) plaques in the brain. Though neurodegenerative diseases such as AD often exhibit neuroinflammation, the anti-inflammatory drugs tested to date have been unsuccessful in improving disease symptoms. In this work, the authors instead increased immune system activity through anti-PD-1 antibody treatment as a means of treating AD.

Using the five familial AD mutations (5XFAD) mouse model of AD, the researchers demonstrated that administration of PD-1 blocking antibody increased the presence of myeloid cells in the brain relative to IgG control treatment. Anti-PD-1-treated animals with advanced stage pathology exhibited improved memory, as determined by the decrease in the number of errors made during the radial arm water maze (RAWM) test. When mice were given two rounds of anti-PD-1, their performance in the test improved over those given only a single treatment round. Subsequent histological analysis of brain sections revealed a decrease in the number and size of Aβ plaques in the antibody-treated cohorts. These plaque reduction results were confirmed using a second mouse model of AD, APP/PS1 mice, which develops more severe manifestations of the disease.

This work highlights the potential to blockade the PD-1 immune checkpoint pathway as a treatment for AD. Currently, various anti-PD-1 treatments are being tested and used for the treatment of cancer. Encouraging safety and toxicity studies in cancer patients provide promise in using PD-1 blocking antibodies as a method of treating AD and other neurodegenerative diseases.

RELATED REPORTS

Plasma p-tau217 is an accurate plasma biomarker of pathologic cerebral changes in patients with Down Syndrome

#VisualAbstract: Anti-tau antibody Semorinemab not shown to slow clinical progression of Alzheimer’s disease

Anti-tau antibody Semorinemab not shown to slow clinical progression of Alzheimer’s disease

Click to read the study in Nature Medicine

Relevant Reading: IFN-γ-dependent activation of the brain’s choroid plexus for CNS immune surveillance and repair

In-Depth [animal study]: C57/BL6-SJL mice with the 5XFAD transgenes were treated with 2 intraperitoneal injections of anti-PD-1 antibody (n=5) or IgG control (n=4) at 250 μg/animal. One week after treatment, the proportion of infiltrating myeloid cells present in the brain was measured by flow cytometry (CD45highCD11b+). The anti-PD-1 group showed a significant increase relative to control (p<0.05). These immune cells were found to also express scavenger receptor A (SRA1), a receptor involved in the clearance of Aβ plaques.

To assess the impact of treatment on memory and spatial learning, the RAWM test was used. Briefly, a water tank contained 6 compartments radiating out from the center, with a submerged escape platform at the end of one compartment. Mice were trained to find the platform on day 1 and tested on day 2. 10-month-old mice were tested one month after a single anti-PD-1 treatment. Compared to the IgG control group (n=6), the treatment group (n=9) performed with significantly fewer errors after 4 trials of testing (p<0.001). When mice received 2 rounds of treatment, each separated by one month, performance was improved to levels comparable to the wild-type, healthy control cohort. Histology of the hippocampus and layer V of the cerebral cortex showed that both treatment schemes resulted in significant decreases in Aβ plaque number and size (percent of tissue area positively stained for Aβ).

These results were confirmed in a second, more aggressive model of AD. APP/PS1 mice, aged 8- and 15-months (n=4 per group), were treated with a single round of anti-PD-1 and examined one month later. Anti-PD-1 treatment led to fewer and overall smaller plaques (p<0.01).

Image: PD

©2016 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Alzheimer’s disease
Previous Post

Increasing testosterone significantly improves sexual function and depressive symptoms in older men

Next Post

Emergency room readmissions not associated with increased cost, mortality

RelatedReports

Brain lesions on MRI linked with subsequent increased stroke risk
Chronic Disease

Plasma p-tau217 is an accurate plasma biomarker of pathologic cerebral changes in patients with Down Syndrome

July 7, 2022
#VisualAbstract: Varenicline improves successful smoking cessation amongst African American daily smokers: KIS-IV Trial
StudyGraphics

#VisualAbstract: Anti-tau antibody Semorinemab not shown to slow clinical progression of Alzheimer’s disease

June 29, 2022
Genetic risk assessment for Alzheimer’s disease does not increase anxiety, depression or stress
Chronic Disease

Anti-tau antibody Semorinemab not shown to slow clinical progression of Alzheimer’s disease

June 17, 2022
Amyloid pathology may be detected decades prior to Alzheimer’s diagnosis
Chronic Disease

Rare APOE missense variants V236E and R251G associated with substantial reduction in risk of Alzheimer disease

June 2, 2022
Next Post
Computed tomography improves diagnostic certainty in the emergency department

Emergency room readmissions not associated with increased cost, mortality

Survivors of adult-onset cancers associated with increased incidence of cardiovascular disease

Survivors of adult-onset cancers associated with increased incidence of cardiovascular disease

Decreased prevalence of HPV among vaccinated young females

Decreased prevalence of HPV among vaccinated young females

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Methamphetamine use associated with cardiovascular disease in hospitalized patients
  • Management of uncomplicated urinary tract infections amongst women in the United States Military Health System highly concordant with guidelines
  • Gout flares associated with a transient increase in subsequent risk of cardiovascular events
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.